Treatment for Wrinkles

Phase-Based Progress Estimates

Effectiveness

Safety

Northwestern University Department of Dermatology, Chicago, IL

Wrinkles

You have a chance of qualifying for this trial. We made sure your application will take less than 5 minutes.

Eligibility

18+

All Sexes

Eligible conditions

Select

Eligibility

18+

All Sexes

Eligible conditions

Select

Study Summary

This study is evaluating whether Botox® or Xeomin® is more effective for the treatment of forehead and glabellar (vertical lines between the eyebrows) wrinkles.

See full description

Treatment Effectiveness

Effectiveness Estimate

1 of 3

Compared to trials

Venus Aime

Botox Cosmetic

Treatment with diluted Radiesse

Study Objectives

This trial is evaluating whether Treatment will improve 2 primary outcomes in patients with Wrinkles. Measurement will happen over the course of At baseline and at 6 months.

Month 6

Change in forehead wrinkle score from baseline to 6 months for botox vs. xeomin

Change in glabellar wrinkle score from baseline to 6 months for botox vs. xeomin

Trial Safety

Safety Estimate

1 of 3

Compared to trials

Venus Aime

Botox Cosmetic

Treatment with diluted Radiesse

Trial Design

2 Treatment Groups

Incobotulinum Toxin A

1 of 2

Onabotulinum Toxin A

1 of 2

Active Control

This trial requires 20 total participants across 2 different treatment groups

This trial involves 2 different treatments. Treatment is the primary treatment being studied. Participants will all receive the same treatment. There is no placebo group. The treatments being tested are not being studied for commercial purposes.

Incobotulinum Toxin A

Drug

The other side of the face will be randomized to receive Incobotulinum Toxin A injections in the glabellar and forehead region of the face.

Onabotulinum Toxin A

Drug

One side of the face will be randomized to receive Onabotulinum Toxin A injections in the forehead and glabellar region of the face.

Trial Logistics

Trial Timeline

Approximate Timeline

Screening: ~3 weeks

Treatment: Varies

Reporting: at baseline and at 6 months

This trial has the following approximate timeline: 3 weeks for initial screening, variable treatment timelines, and roughly at baseline and at 6 months for reporting.